Evidence map›Paper›PMID 33692623›Full record

ArticleInternational journal of nanomedicine2021

Self-Assembled DNA Nanostructure as a Carrier for Targeted siRNA Delivery in Glioma Cells.

Yanghao Zhou, Qiang Yang, Feng Wang, Zunjie Zhou, Jing Xu, Si Cheng, Yuan Cheng

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. miR-21 Responsive Nanocarrier Targeting Ovarian Cancer Cells.Computational and structural biotechnology journal · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Review
  12. Small Interfering RNA for Gliomas Treatment: Overcoming Hurdles in Delivery.Frontiers in cell and developmental biology · 2022
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yanghao ZhouDepartment of Neurosurgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.ORCID 0000-0002-5968-8618
Qiang YangDepartment of Neurosurgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.ORCID 0000-0002-0702-9063
Feng WangDepartment of Neurosurgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Zunjie ZhouDepartment of Neurosurgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Jing XuDepartment of Neurosurgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Si ChengDepartment of Orthopedics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Yuan ChengDepartment of Neurosurgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRNA interference is a promising therapy in glioma treatment. However, the application of RNA interference has been limited in glioma therapy by RNA instability and the lack of tumor targeting. Here, we report a novel DNA tetrahedron, which can effectively deliver small interfering RNA to glioma cells and induce apoptosis.

methodssiRNA, a small interfering RNA that can suppress the expression of survivin in glioma, was loaded into the DNA tetrahedron (TDN). To enhance the ability of active targeting of this nanoparticle, we modified one side of the DNA nanostructure with aptamer as1411 (As-TDN-R), which can selectively recognize the nucleolin in the cytomembrane of tumor cells. The modified nanoparticles were characterized by agarose gel electrophoresis, dynamic light scattering, and transmission electron microscopy. The serum stability was evaluated by agarose gel electrophoresis. Nucleolin was detected by Western blot and immunofluorescence, and targeted cellular uptake was examined by flow cytometry. The TUNEL assay, flow cytometry, and Western Blot were used to detect apoptosis in U87 cells. The gene silencing of survivin was examined by qPCR, Western Blot, and immunofluorescence.

resultsAs-TDN-R alone showed better stability towards siRNA, indicating that TDN was a good siRNA protector. Compared with TDN alone, there was increased intercellular uptake of As-TDN-R by U87 cells, evidenced by overexpressed nucleolin in glioma cell lines. TUNEL assay, flow cytometry, and Western Blot revealed increased apoptosis in the As-TDN-R group. The downregulation of survivin protein and mRNA expression levels indicated that As-TDN-R effectively silenced the target gene.

conclusionThe novel nanoparticle can serve as a good carrier for targeting siRNA delivery in glioma. Further exploration of the DNA nanostructure can greatly promote the application of DNA-based drug systems in glioma.

Indexed as

Gene Transfer TechniquesApoptosisAptamers, NucleotideCell DeathCell Line, TumorCell SurvivalDNADown-RegulationEndocytosisGene SilencingGliomaHumansHuman Umbilical Vein Endothelial CellsNanostructuresNucleolinOligodeoxyribonucleotidesAGRO 100Aptamers, NucleotideBIRC5 protein, humanDNANucleolinOligodeoxyribonucleotidesPhosphoproteinsRNA-Binding ProteinsRNA, Small InterferingSurvivinapoptosisaptamerDNA tetrahedronnanomedicineRNA interferencetumor targeting

Identifiers

PMID33692623
PMCPMC7938230
OpenAlexW3135882856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.